Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials
Marcella Sarzotti‐Kelsoe(Duke Medical Center), Anita Simkins(AlphaVax (United States)), Daniel A. Ozaki(Duke University), Naana Cleland(Henry M. Jackson Foundation), Leila K. Needham(Duke University), Tony Tarragona-Fiol(Imperial College London), Josephine H. Cox(International AIDS Vaccine Initiative), Timothy A. Stiles, John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Thomas N. Denny(Duke University), Gwynneth Stevens(Development Bank of Southern Africa), Isaac R. Rodriguez‐Chavez(National Institutes of Health)
Cited by 59
Related Papers
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
|New England Journal of Medicine|2013|586
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|557
Functions of IL-4 and Control of Its Expression
|Critical Reviews in Immunology|2017|354